Pharmaceuticals company Jagsonpal Pharmaceuticals announced Q2FY26 results Revenue for Q2FY26 stood at Rs 745 million, remaining steady amid GST transition adjustments, maintaining stability on a high base. Operating EBITDA stood at Rs 181 million with margins of 24.3%. Profit rose to Rs 126 million in Q2FY26, with margins expanding 154 bps to 16.9%. Healthy cash balance of Rs 1,604 million as of September 30, 2025, post dividend of 125% (Rs 2.5 per share) leading to a payout of Rs 166 million. Manish Gupta, Managing Director, Jagsonpal Pharmaceuticals, said: “We are pleased to report a resilient performance reflecting our continued focus on sustainable growth and operational excellence. The first half of FY26 marked a strong showing, with revenue rising 10.2% YoY to Rs 1,501 million, EBITDA (pre-ESOP) grew 8.8% YoY to Rs 338 million, and PAT witnessing a 39.2% YoY increase to Rs 234 million. This performance underscores our consistent execution, disciplined cost management, complementing the inherent strength of our diversified portfolio. We welcome GST 2.0- a step towards affordable healthcare. With our “Patient First” approach, we have fully passed the benefits through reduced prices. The transition led to temporary moderation in sales and trade movement. Despite this, revenue for Q2FY26 stood at Rs 745 million, Operating EBITDA at Rs 180 million with PAT growing 9.7% YoY to Rs 126 million. We have strengthened the leadership team by onboarding Amrut Medhekar as Chief Operating Officer and Nirav Vora as Chief Financial Officer who will play a key role going forward. We continue to build our brands and uphold a legacy built on trust, quality, and integrity, fostering lasting relationships with our stakeholders who remain at the heart of our growth journey.” Result PDF